A Phase 2/3 interventional study of Ravulizumab in Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 16 sites in 7 countries. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is the only one that started in 2022, is one of 3 in phase 2/3, and was the 6th registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Argentina, Canada and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2014; this study’s year is marked. 1 started in 2022.
This study's enrollment of 12 is below the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.
Median enrollment 40 across the 8 interventional studies, 75 across the 3 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Neuromyelitis Optica by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06724809Phase 3Alexion Pharmaceuticals, Inc.Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment. During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks.
Drug: Ravulizumab
Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight. During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight.
Also known as: ALXN1210, Ultomiris
Change From Baseline in the Annualized Relapse Rate at Week 50
Time frame: Baseline, Week 50
Time to First Adjudicated On-trial Relapse through Week 50
Time frame: Baseline through Week 50
Change From Baseline in Expanded Disability Status Scale Score At Week 50
The score ranges are 0 to 10, higher score indicates worse outcome.
Time frame: Baseline, Week 50
Change From Baseline in Hauser Ambulation Index at Week 50
The score ranges are 0 to 9, higher score indicates worse outcome.
Time frame: Baseline, Week 50
Change From Baseline in Visual Acuity at Week 50
Time frame: Baseline, Week 50
Change From Baseline in Confrontational Visual Fields at Week 50
Time frame: Baseline, Week 50
Change From Baseline in Color Vision at Week 50
Time frame: Baseline, Week 50
Serum Ravulizumab Concentration
Time frame: Predose and postdose (at end of infusion) on Day 1, Weeks 2, 10, 18, 26, and 42, and predose on Week 50
Change from Baseline in Free Serum Complement Component 5 (C5) Concentration Over Time Through Week 50
Time frame: Baseline through Week 50
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2026, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →